Guggenheim Starts Mineralys Therapeutics, Inc. (MLYS) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil rises as Trump repeats Iran attack threat
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Stifel positive on Mineralys Therapeutics due to 'seemingly unlimited upside market'
March 7, 2023 10:55 AM ESTStifel analyst Annabel Samimy initiated a Buy rating and $45 per share price target on Mineralys Therapeutics (NASDAQ: MLYS) in a note to clients on Tuesday.
The analyst acknowledged that the hypertension market has been in "decades-long stasis, with the level of uncontrolled and... More
